ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Business deals

Takeda and rivals chase cancer therapy prize through M&A

Shire's profits needed to fund drugmaker's hunt for next-gen treatments

A researcher works at Takeda's rival, Ono Pharmaceutical. Ono found great success with its blockbuster cancer medication Opdivo. (Photo courtesy of Ono Pharmaceutical)

TOKYO -- The rapidly advancing field of cancer immunotherapy is pushing Takeda Pharmaceutical and its global competitors to make a series of bold deals in order to position themselves in one of the most promising areas in pharmaceuticals.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more